Cooperative Agreement U54CA295336
Award Date
9/20/24
Completion Date
8/31/29
Dollars Obligated
$2.7M
Federal Agency
National Cancer Institute
Federal Grant Program
93.397
Assistance Type
Cooperative Agreement
Place of Performance
Baltimore, MD 21205, USA
Similar Awards
The National Cancer Institute awarded a $1,326,910 Cooperative Agreement (CFDA 93.397 - Cancer Centers Support Grants) to Howard University to establish the Howard-Johns Hopkins Comprehensive Alliance in Cancer Research, Education, and Equity (H2CAREE) initiative. This 5-year project aims to advance cancer care and health equity through a partnership between Howard University and the Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center. Key objectives include:
Increasing cancer...
This federal Cooperative Agreement award of $1,887,583 was provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393). The goal of the award is to advance cancer control equity through community-engaged, multilevel research interventions that address social determinants of health and their impact on adverse cancer control outcomes.
The key products and services to be delivered under this 5-year award include:
Developing innovative,...
This $2,190,123 Project Grant award from the National Cancer Institute (CFDA 93.397 - Cancer Centers Support Grants) provides funding to The Johns Hopkins University to conduct translational research aimed at reducing prostate cancer mortality. The award supports a Specialized Program of Research Excellence (SPORE) focused on advancing new insights about the role of adaptive changes in the hormonal axis, DNA-repair mechanisms, and the immune system in prostate cancer pathobiology. The goal is...
This $998,444 cooperative agreement award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will fund a pragmatic trial to implement and evaluate a primary care-based cancer survivorship care delivery intervention in 8 community health clinics in Texas. The goal is to improve outcomes for underserved cancer survivors by enhancing the capacity of primary care teams to provide high-quality, coordinated survivorship care. The study will involve: (1)...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $589,459 to The Johns Hopkins University to conduct research on lung cancer health disparities in African American populations. The key focus is to: (1) identify a novel African American-specific non-coding RNA (AA-pcRNA) that is expressed in lung cancer tissue from African Americans but not Caucasians or Asians, and characterize its...
The National Cancer Institute (NCI) awarded a $1,620,203 Cooperative Agreement (CFDA 93.393 - Cancer Cause and Prevention Research) to the University of Southern California (USC) on July 23, 2024. The purpose of this 5-year project is to identify factors associated with prostate cancer progression and survival in African American men through the RESPOND cohort. The project aims to:
Examine multi-level provider, geospatial, and personal factors that define access to care and their...
The Department of Health and Human Services, National Cancer Institute (NCI) awarded a $720,252 Cooperative Agreement (U01CA296432) to the Dana-Farber Cancer Institute, Inc. through the Cancer Cause and Prevention Research program (CFDA 93.393). The project, titled "Characterizing Genetic Risk of Cancer Across Diverse Populations Through Multi-Ancestry Epigenome Profiling and Chromatin QTL Discovery," aims to identify novel cancer-associated chromatin quantitative trait loci (cQTLs)...
This $846,735 Cooperative Agreement award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) aims to maintain and expand the core Bioconductor software infrastructure to support advanced cancer genomics research. Key objectives include:
Enhancing infrastructure for multimodal experiments and spatial transcriptomics, and connecting Bioconductor with image analysis tools for statistical analysis of histopathology data.
Transitioning Bioconductor's data and...
The U19CA291431 federal Cooperative Agreement award supports the "Massachusetts Partnership for Community-Engaged Cancer Control Equity" (MASS PCECCE) project through the National Cancer Institute's Cancer Cause and Prevention Research program (CFDA 93.393). The $1,971,041 award, made on August 16, 2024, aims to strengthen the capacity of community health centers and community organizations to improve cancer screening, tobacco treatment, social capital, civic engagement, and digital...
The National Cancer Institute (NCI) has awarded a $686,993 Cooperative Agreement under the Cancer Cause and Prevention Research Program (CFDA 93.393) to The Trustees of Columbia University in the City of New York to implement electronic health record (EHR)-based strategies and decision support for hereditary breast and ovarian cancer (HBOC) genetic testing among multiethnic women. The project aims to address the significant underutilization of HBOC genetic testing, particularly among women of...